Last edition
News about "Lupin"
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Lupin | 14/11/2025 | By Dineshwori
Lupin Receives EIR from US FDA for its Pithampur Unit-3 Facility
Following an inspection in July 2025, Lupin received the USFDA’s Establishment Inspection Report (EIR) for its Pithampur Unit-3 facility.
Lupin | 06/11/2025 | By Dineshwori | 100
Lupin Expands US Footprint with New Corporate Offices in Bridgewater, New Jersey
Lupin has inaugurated its new corporate offices at 100 Somerset Corporate Blvd, Bridgewater, New Jersey, expanding its presence in the state where it already operates manufacturing and research facilities.
Lupin | 28/10/2025 | By Dineshwori
Lupin Launches Generic Version of Ravicti in the US
Global pharma major Lupin has launched an authorised generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States.
Lupin | 24/10/2025 | By Dineshwori
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Lupin | 13/10/2025 | By Dineshwori | 125
US FDA Completes Pre-Approval Inspection at Lupin's Somerset Facility with One Observation
The US Food and Drug Administration (FDA) has completed a pre-approval inspection of Lupin’s manufacturing facility in Somerset, New Jersey, USA, with one observation.
Lupin | 11/10/2025 | By Dineshwori | 254
Lupin Launches Strategic Partnership Programme to Expand Reach of PrecisionSphere
Global pharma major Lupin has launched a strategic partnership programme aimed at expanding the reach of PrecisionSphere – the long-acting injectable (LAI) platform developed by its subsidiary, Nanomi.
Lupin | 09/10/2025 | By Dineshwori
Lupin to Invest USD 250 Million in New USA Respiratory Drug Manufacturing Facility in Florida
Lupin has announced plans to invest USD 250 million over the next five years to establish a new state-of-the-art manufacturing facility in Coral Springs, Florida. The facility will focus on producing over 25 essential respiratory medicines, including albuterol inhalers.
Lupin | 09/10/2025 | By Darshana
US FDA Classifies Lupin's Pithampur Unit-2 as Official Action Indicated
The US Food and Drug Administration (FDA) has concluded its inspection of Lupin’s Pithampur Unit-2 manufacturing facility, issuing a Form 483 with four observations.
Lupin | 04/10/2025 | By Dineshwori | 348
Lupin Launches Liraglutide Injection in US
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
Lupin | 04/10/2025 | By Dineshwori | 103
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy